Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2021
Randomized Phase III Trial Evaluating Radiation Following Surgical Excision for Good-Risk Ductal Carcinoma In Situ: Long-Term Report From NRG Oncology/RTOG 9804.
Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05637216 (A Pilot Study of Losartan to Reduce Radiation Induced Fibrosis in Breast Cancer Patients), which is not on this map. Cited by 44 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Pilot Study of Losartan to Reduce Radiation Induced Fibrosis in Breast Cancer Patients
Who cites it
44 citing papers in PubMed, 3 syntheses or guidelines pooled it, 95 citations in OpenAlex.
- Management of Ductal Carcinoma In Situ: An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline.Current oncology (Toronto, Ont.) · 2024Guideline
- Outcomes from low-risk ductal carcinoma in situ: a systematic review and meta-analysis.Breast cancer research and treatment · 2024Pooled it
- Advances in breast cancer treatment: a systematic review of preoperative stereotactic body radiotherapy (SBRT) for breast cancer.Radiation oncology (London, England) · 2024Pooled it
- Racial and Ethnic Disparities in Outcomes After Breast-Conserving Therapy and Endocrine Therapy for DCIS: A Post-Hoc Analysis of the NSABP B-35 Randomized Clinical Trial.Annals of surgical oncology · 2023Trial
- Radiotherapy for Ductal Carcinoma In Situ: Toxicity, Quality of Life, and Decisional Regret at a Tertiary Cancer Center.Cancers · 2026Article
- Impact of Tamoxifen Only After Lumpectomy for "Good-Risk" Duct Carcinoma In Situ: Combined Analysis of the NRG Oncology/RTOG 9804 and ECOG-ACRIN E5194 Trials.International journal of radiation oncology, biology, physics · 2026Article
- Article
- Article
- The impact of immune microenvironment on local control of ductal carcinoma in situ receiving breast conservative therapy.Breast cancer research : BCR · 2026Article
- Relative Effects of Brachytherapy and Beam Radiation for DCIS on Subsequent Invasive Events.Biomedicines · 2025Article
- Current pattern of care in radiation therapy for DCIS in Australia and New Zealand - where are we heading?Breast (Edinburgh, Scotland) · 2025Article
- Lumpectomy surgery for large ductal carcinoma in situ.Breast cancer research and treatment · 2025Article
- Should All Low-Grade Ductal CarcinomaWorld journal of oncology · 2025Article
- Update on the management of ductal carcinoma in situ of the breast: current approach and future perspectives.Japanese journal of clinical oncology · 2025Review
- An early economic evaluation of active surveillance for low-risk ductal carcinomaFuture oncology (London, England) · 2024Article
- A Nomogram Using Imaging Features to Predict Ipsilateral Breast Tumor Recurrence After Breast-Conserving Surgery for Ductal Carcinoma In Situ.Korean journal of radiology · 2024Article
- Ductal carcinoma in situ and cause-specific mortality among younger and older postmenopausal women: the Women's Health Initiative.Breast cancer research and treatment · 2024Article
- Tools to Guide Radiation Oncologists in the Management of DCIS.Healthcare (Basel, Switzerland) · 2024Review
- Progression from ductal carcinoma in situ to invasive breast cancer: molecular features and clinical significance.Signal transduction and targeted therapy · 2024Review
- Lumpectomy without radiation for ductal carcinoma in situ of the breast: 20-year results from the ECOG-ACRIN E5194 study.NPJ breast cancer · 2024Article
Corrections and comments
- Commented on by
Authors and funding
19 authors at 12 institutions in 2 countries.
Funding
Abstract
purposeTo our knowledge, NRG/RTOG 9804 is the only randomized trial to assess the impact of whole breast irradiation (radiation therapy [RT]) versus observation (OBS) in women with good-risk ductal carcinoma in situ (DCIS), following lumpectomy. Long-term results focusing on ipsilateral breast recurrence (IBR), the primary outcome, are presented here. PATIENTS AND
methodsEligible patients underwent lumpectomy for DCIS that was mammogram detected, size ≤ 2.5 cm, final margins ≥ 3 mm, and low or intermediate nuclear grade. Consented patients were randomly assigned to RT or OBS. Tamoxifen use was optional. Cumulative incidence was used to estimate IBR, log-rank test and Gray's test to compare treatments, and Fine-Gray regression for hazard ratios (HRs).
resultsA total of six hundred thirty-six women were randomly assigned from 1999 to 2006. Median age was 58 years and mean pathologic DCIS size was 0.60 cm. Intention to use tamoxifen was balanced between arms (69%); however, actual receipt of tamoxifen varied, 58% RT versus 66% OBS (
conclusionRT significantly reduced all and invasive IBR for good-risk DCIS with durable results at 15 years. These results are not an absolute indication for RT but rather should inform shared patient-physician treatment decisions about ipsilateral breast risk reduction in the long term following lumpectomy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.